SIARI VERONA

SIARI VERONA: [128957] Home page macrotipologia

Sfoglia

01 Contributo in rivista 75221
- 01.01 Articolo in Rivista 69991
- 01.02 Recensione in Rivista 2994
- 01.03 Scheda bibliografica 283
- 01.04 Nota a Sentenza 852
- 01.05 Abstract in rivista 1021
- 01.06 Traduzione in rivista 80

02 Contributo in volume 24574
- 02.01 Contributo in volume (Capitolo o Saggio) 21137
- 02.02 Prefazione/Postfazione 556
- 02.03 Breve introduzione 330
- 02.04 Voce (in dizionario o enciclopedia) 1183
- 02.05 Traduzione in volume 129
- 02.06 Recensione in volume 25
- 02.07 Schede di Catalogo 1214

03 Libro 4166
- 03.01 Monografia o trattato scientifico 3794
- 03.02 Concordanza 0
- 03.03 Indice 21
- 03.04 Bibliografia 13
- 03.05 Edizione critica di testi/di scavo 147
- 03.06 Pubblicazione di fonti inedite 25
- 03.07 Commento scientifico 24
- 03.08 Traduzione di libro 142

04 Contributo in atti di convegno 16969
- 04.01 Contributo in atti di convegno 14012
- 04.02 Abstract in Atti di convegno 2214
- 04.03 Poster 743

05 Brevetto 131
- 05.01 Brevetto 131

06 Curatela 2817
- 06.01 Curatela 2817

07 Altra tipologia 5081
- 07.01 Composizione 1
- 07.02 Disegno 17
- 07.03 Design 0
- 07.04 Performance 11
- 07.05 Esposizione 7
- 07.06 Mostra 105
- 07.07 Manufatto 0
- 07.08 Prototipo d'arte e relativi progetti 0
- 07.09 Cartografia 7
- 07.10 Banca dati 86
- 07.11 Software 15
- 07.12 Altro 1262
- 07.13 Doctoral Thesis 2790
- 07.14 Rapporti di ricerca 481
- 07.15 Rapporti di ricerca di altri Atenei 235
- 07.16 Relazioni scientifiche Assegnisti di Ricerca 64

Prodotti recenti

Neutrophil-lymphocyte ratio is associated with worse outcomes in patients with cirrhosis: insights from the PRO-LIVER Registry

Background Liver cirrhosis (LC) is a leading global cause of morbidity and mortality, with inflammation playing a key role in disease progression and clinical complications of LC. The Neutrophil/Lymphocyte Ratio (NLR), a readily available marker of systemic inflammation, has been linked to short-term adverse outcomes in LC, but data on long-term follow-up are limited. This study aimed to investigate the relationship between NLR and long-term all-cause mortality in an unselected cohort of LC p...

Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study

Background/Aims: Adjuvant systemic therapy has been proposed in patients at high-risk of hepatocellular carcinoma (HCC) recurrence. This study assessed the outcomes of a real-world cohort treated with either resection or ablation, stratified according to the IMbrave050 trial criteria. Methods: We selected, from the Italian Liver Cancer database, 1150 patients with HCC treated with upfront resection ( n = 483, 64.2 % high-risk) or ablation ( n = 667, 49.6 % high risk), fulfilling the inclusion...

Platelet Functional Profile Is Altered in Metabolic Dysfunction-Associated Steatotic Liver Disease

Background and AimsMetabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease, often progressing to fibrosis and up to cirrhosis. Platelet activation plays a potential role in MASLD progression, but its functional profile across disease stages remains unclear. This study aimed to characterise the platelet functional profile and phenotype in patients with MASLD <= F2 and F3-F4 fibrosis compared to healthy controls.MethodsWe analysed biomarke...

Outcome of hepatic resection for HCC in ideal and non-ideal candidates

Background: The Barcelona Clinic Liver Cancer staging system considers, among patients with HCC, "ideal candidates" (ICs) for hepatic resection (HR) those with a single lesion, normal bilirubin, and without clinically significant portal hypertension (CSPH). We compared the outcome of HR between ICs and non-ICs. Methods: Retrospective analysis was conducted on Child-Pugh A patients. CSPH was defined by the presence of gastroesophageal varices and/or platelet count <100,000/mm(3). Hyperbilir...

Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real-World Database

Background and Aims Hepatitis B (HBV) and Hepatitis Delta virus (HDV) infection have undergone significant changes in Italy over the past few decades, but reliable and updated prevalence of chronic hepatitis B (CHB) and Delta (CHD) data are lacking. The aim of the study was to describe the epidemiology of CHB and CHD in Italy in 2024, based on real-world data.Methods The number of patients with a healthcare expenditure exemption for CHB (016.070.32) and CHD (016.070.33) was obtained from 21 R...

Scopri

Accesso al fulltext

no fulltext100625
open15047
restricted6990
reserved6013
embargoed195
partially open70
mixed17

CATALOGO DEI PRODOTTI DELLA RICERCA

SIARI VERONA: [128957] Home page macrotipologia

Prodotti recenti

Neutrophil-lymphocyte ratio is associated with worse outcomes in patients with cirrhosis: insights from the PRO-LIVER Registry

Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study

Platelet Functional Profile Is Altered in Metabolic Dysfunction-Associated Steatotic Liver Disease

Outcome of hepatic resection for HCC in ideal and non-ideal candidates

Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real-World Database

Scopri

Tipologia

Autore

Data di pubblicazione

Editore

Rivista

Serie

Settore disciplinare

Keyword

Lingua

Accesso al fulltext